Baumgartner H, Hohmeister R, Blumenberg-Novoselac N
Wilhelm Schulthess Klinik, Zurich, Switzerland.
J Int Med Res. 1988 May-Jun;16(3):189-96. doi: 10.1177/030006058801600304.
An observer-blind three-period crossover study of flurbiprofen, indomethacin and naproxen was carried out in 56 patients with rheumatoid arthritis. The drugs were scheduled as two oral doses early in the day with a rectal suppository at night. The aims were to compare efficacy, principally as relief of night pain and morning stiffness, and safety. Flurbiprofen was clearly the most beneficial drug. Advantages over the comparators were demonstrated in terms of shorter duration of morning stiffness, reduced severity of night pain (compared with naproxen) and in the improvement in sleep quality experienced by the patients. Excellent tolerability of flurbiprofen was seen, it being equivalent to naproxen and superior to indomethacin. The results demonstrate that nocturnal and early daytime provision of flurbiprofen is a highly effective strategy for controlling the nocturnal pain and morning stiffness of rheumatoid arthritis.
对56例类风湿性关节炎患者进行了一项观察者盲法三阶段交叉研究,比较氟比洛芬、吲哚美辛和萘普生。药物给药方案为每日清晨口服两次,夜间直肠给药一次。目的是比较疗效(主要是缓解夜间疼痛和晨僵)和安全性。氟比洛芬显然是最有益的药物。与对照药物相比,氟比洛芬在缩短晨僵持续时间、减轻夜间疼痛严重程度(与萘普生相比)以及改善患者睡眠质量方面具有优势。氟比洛芬耐受性良好,与萘普生相当,优于吲哚美辛。结果表明,夜间和清晨给予氟比洛芬是控制类风湿性关节炎夜间疼痛和晨僵的高效策略。